35 stories found
Financial analysts evaluate the competitive positioning, pipeline strength, and valuation metrics of Vertex and Regeneron to determine which biotech giant offers better near-term investment potential.
Attorneys have initiated securities fraud class action lawsuits targeting several publicly traded companies, including Wix.com, Regeneron, and GoDaddy. The filings allege misleading statements contributed to recent shareholder losses.
Market experts are evaluating Regeneron Pharmaceuticals' pipeline developments and recent earnings to determine whether institutional investors remain optimistic or cautious about its shares.
Several companies, including Plexus, Preformed Line Products, Endeavour Silver, Cactus, Spok, Insperity, Arxis, CONMED, and Everest Group, reported their latest quarterly earnings, with most beating analyst expectations for EPS and revenue. Starbucks, however, saw a significant decline in international revenue, and Pilgrim's Pride missed on both EPS and revenue.
Regeneron Pharmaceuticals expects to incur a pre-tax in-process research and development (IPR&D) charge of approximately $127 million in the second quarter.
An analysis investigates if Regeneron Pharmaceuticals' stock is underperforming when compared to the Dow Jones Industrial Average.
Regeneron Pharmaceuticals saw its stock decline after a melanoma study conducted by the company failed to meet its key endpoint, impacting investor confidence.
US biotech giant Regeneron Pharmaceuticals has attributed a recent production pause and subsequent hit to its overall margin to unexpected facility repairs at its large manufacturing plant in Limerick, Ireland.
Regeneron Pharmaceuticals reported first-quarter earnings that topped analyst estimates, largely attributed to the strong momentum of its drug Dupixent.
An earnings preview outlines expectations for Regeneron Pharmaceuticals' upcoming financial report.
Piper Sandler has upgraded Regeneron Pharmaceuticals to an 'overweight' rating, citing strong performance from its drug Dupixent and the potential of its robust pipeline.
An analysis questions whether Regeneron Pharmaceuticals stock is underperforming relative to the broader Nasdaq index.
Robbins Geller Rudman & Dowd LLP has announced a September 14, 2026 deadline for investors with substantial losses in Regeneron Pharmaceuticals to lead a securities class action lawsuit.
The pharmaceutical company is recalibrating its development pipeline and trial protocols after evaluating intermediate data showing inconsistent efficacy for its cancer treatment candidate.
Analysts are evaluating whether Biohaven's recent deal with Regeneron Pharmaceuticals could serve as a major catalyst for its drug development pipeline.
Regeneron Pharmaceuticals (REGN) experienced a setback in its second quarter due to disappointing results from recent clinical trials, affecting its financial performance.
Hedge funds are reportedly evaluating top AI-powered healthcare stocks, with Eli Lilly and Company (LLY) and Regeneron Pharmaceuticals, Inc. (REGN) being highlighted as potential investment opportunities in this sector.
Following recent Q1 updates, analysts from Morgan Stanley, Canaccord, Deutsche Bank, and Bernstein have adjusted price targets for several companies. This includes both increases for firms like NextEra Energy, Park Hotels & Resorts, Venture Global, Devon Energy, Golar LNG, ConocoPhillips, Chevron, and Arrowhead Pharmaceuticals, and cuts for Joby Aviation and Baker Hughes, with Canaccord citing a disappointing event for Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals experienced a decline in its stock value following the failure of a late-stage clinical trial for a melanoma treatment.
A range of companies, including Landmark Bancorp, The Cheesecake Factory, and Mattel, have announced their latest quarterly financial results, detailing their earnings per share and revenue figures.
TD Cowen has increased its price target for Regeneron Pharmaceuticals, signaling optimism for the company's financial performance ahead of its fiscal first-quarter results.
Telix Pharmaceuticals and Regeneron Pharmaceuticals have announced a strategic collaboration to co-develop novel radiopharmaceutical therapies, combining their expertise in oncology and drug development.
An article examines the investment potential of Regeneron Pharmaceuticals, Inc. (REGN) for prospective stock purchasers.
Analysts are offering their latest comments and assessments regarding Regeneron Pharmaceuticals (REGN).
Market review indicates that Regeneron Pharmaceuticals shares are currently delivering stronger returns compared to the broader healthcare sector, driven by pipeline developments and commercial momentum.
The law firm Levi & Korsinsky has released shareholder notices reminding investors of upcoming lead plaintiff deadlines in active securities fraud lawsuits against several major corporations. The alerts specifically cover cases involving Intuit, Regeneron Pharmaceuticals, Wix.com, Insulet, and other publicly traded entities.
Regeneron Pharmaceuticals announced a quarterly dividend of $0.94 per share. This financial declaration is a routine update for shareholders.
Several MedTech and Biotech companies, including TransMedics Group, Insulet Corporation, and Regeneron Pharmaceuticals, have seen their stock price targets cut by analysts. This raises questions about their continued growth opportunities in the respective sectors.
An analysis evaluates whether Regeneron Pharmaceuticals, Inc. (REGN) is currently a good stock to buy for investors.
Wall Street analysts are offering predictions on whether Regeneron Pharmaceuticals stock will climb or sink, reflecting varying market sentiments.
Billionaire investor Steve Cohen reportedly considers Regeneron Pharmaceuticals (REGN) to be among the best biotech stocks for investment.
Regeneron Pharmaceuticals experienced a slide in its share price, even after reporting better-than-expected financial results for the first quarter.
Regeneron Pharmaceuticals (REGN) has announced a new collaboration agreement with Telix Pharmaceuticals Limited, signaling a joint effort in pharmaceutical development.
Biotechnology company Regeneron Pharmaceuticals expects to incur approximately $102 million in pre-tax in-process research and development charges for the first quarter.
Several financial firms have issued new ratings, price targets, or coverage initiations for biotech and pharmaceutical companies including Beam Therapeutics, Krystal Biotech, 4D Molecular Therapeutics, BioMarin Pharmaceutical, Vertex Pharmaceuticals, CRISPR Therapeutics AG, Regeneron Pharmaceuticals, and UniQure.